



Review Article

Nano-carrier-based Delivery of CRISPR-Cas9 for Oncolytic Gene Therapy: Insights from Xenograft Models

Mehran Bahmani 

Department of Basic Sciences, Faculty of Nursing and Midwifery, Kurdistan University of Medical Sciences, Sanandaj, Iran

* **Corresponding author:** Mehran Bahmani, Department of Basic Sciences, Faculty of Nursing and Midwifery, Kurdistan University of Medical Sciences, Sanandaj, Iran. Email: mehranbahmani4521@gmail.com

ARTICLE INFO

Article History:

Received: 15/02/2025

Revised: 22/03/2025

Accepted: 07/04/2025

Published: 29/04/2025



Keywords:

Gene therapy

Nanocarrier delivery system

Oncolytic cancer therapy

Viral and non-viral vector

Xenograft tumor model

ABSTRACT

The CRISPR-Cas9 system has revolutionized genome editing, offering unprecedented precision and efficiency in gene modification. Its potential in cancer therapy, particularly oncolytic gene therapy, has garnered significant attention, especially with the development of advanced delivery platforms. However, effective and safe *in vivo* delivery of CRISPR components remains a major barrier to clinical translation. This review provides a comprehensive overview of viral and non-viral nanocarrier systems for CRISPR-Cas9 delivery, with a particular focus on their application in xenograft models of cancer. The present study aimed to bridge the gap between molecular innovation and therapeutic application by evaluating the efficiency and safety of CRISPR-Cas9 delivery systems in preclinical oncology models. The mechanisms and classifications of viral vectors, including adeno-associated viruses (AAV), lentivirus, and adenovirus, were emphasized, highlighting their strengths in gene transfer efficiency, while addressing concerns over immunogenicity, genome integration, and scalability. Subsequently, non-viral nanocarriers, including lipid nanoparticles (LNPs), polymeric systems, dendrimers, and metallic nanoparticles, have emerged as safer and more customizable alternatives. Key considerations, including stability, endosomal escape, payload capacity, and tumor targeting, are evaluated, supported by findings from recent xenograft-based studies. A direct comparison between viral and non-viral systems was presented, emphasizing differences in transfection efficiency, biosafety, immunological responses, and gene-editing precision in preclinical tumor models. The clinical relevance of CRISPR-based oncolytic strategies was examined, along with their integration with other cancer therapies. Additionally, the emerging challenges of immune evasion, tumor heterogeneity, and delivery barriers were evaluated. In addition, the regulatory and ethical dimensions surrounding genome editing in cancer therapy are addressed, including long-term safety concerns, germline editing considerations, and global disparities in clinical oversight. The discussion concluded with an examination of future perspectives, highlighting strategic improvements in delivery technologies and validation pipelines. Xenograft models were proposed as a means to accelerate clinical translation.

1. Introduction

Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein 9 (Cas9) have revolutionized the field of gene editing by offering a precise, programmable, and relatively simple method for modifying specific genomic sequences¹. Originally discovered as a part of the adaptive immune system in bacteria and archaea, CRISPR-Cas9 has been repurposed for

targeted gene editing in eukaryotic systems². The system relies on a guide RNA (gRNA) to direct the Cas9 endonuclease to a complementary DNA sequence, where it introduces a double-stranded break. The cell's natural repair mechanisms, non-homologous end joining (NHEJ) or homology-directed repair (HDR), then alter the DNA sequence, enabling knock-out or knock-in of genes. Due to

Cite this paper as: Bahmani M. Nano-Carrier-Based Delivery of CRISPR-Cas9 for Oncolytic Gene Therapy: Insights from Xenograft Models. 2025; 4(2): 12-21. DOI: 10.58803/jlar.v4i2.66



The Author(s). Published by Rovedar. This is an open-access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

its efficiency and flexibility, CRISPR-Cas9 is now a cornerstone of modern genetic therapies, including CAR-T cell engineering, tumor suppressor reactivation, especially in oncology³.

Despite the potential of CRISPR-Cas9, its clinical translation heavily depends on the efficiency and safety of its delivery system⁴. Efficient delivery ensures adequate gene editing at the target site while minimizing off-target effects and systemic toxicity⁴. Delivery vehicles must overcome several biological barriers, such as degradation by nucleases, immune recognition, and poor cellular uptake⁵. Two main classes of delivery systems have emerged, including viral

vectors and non-viral nanocarriers⁶. Viral vectors such as adeno-associated viruses (AAVs), lentiviruses, and adenoviruses offer high transduction efficiency but pose challenges including immunogenicity, limited cargo capacity, and risk of insertional mutagenesis⁶. In contrast, non-viral systems such as lipid nanoparticles (LNPs), polymer-based carriers, and inorganic nanostructures offer customizable surface properties, reduced immunogenicity, and scalable production, but often suffer from lower gene-editing efficiency⁷. Thus, selecting an appropriate delivery system is critical, especially in cancer gene therapy, where both safety and efficacy are paramount (Figure 1).




Figure 1. Schematic representation of clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein 9 delivery to tumor cells using nanocarriers. The process involves intravenous injection, systemic circulation, and tumor targeting, cellular uptake by tumor cells, endosomal escape, and subsequent nuclear localization of Cas9-sgRNA complexes leading to targeted gene editing (Figure designed by Biorender).

To evaluate the clinical potential of CRISPR-Cas9-based therapies, preclinical studies often utilize xenograft models, in which human tumor cells are implanted into immunodeficient mice⁸. These models recapitulate key aspects of the human tumor microenvironment, allowing for *in vivo* assessment of delivery efficiency, biodistribution, genome editing activity, and safety profiles⁹. Xenograft models are particularly valuable in cancer research due to their ability to reflect human-specific responses to gene editing tools, especially when testing oncolytic strategies¹⁰. These models help to identify off-target effects, immune responses, and therapeutic outcomes that may not be evident in *in vitro* systems⁹. Hence, xenograft models serve as an essential bridge between bench research and clinical trials. The present review aimed to evaluate the current strategies for CRISPR-Cas9 delivery using viral and non-viral nanocarriers, with a specific focus on their application in oncolytic gene therapy.

2. Viral nanocarriers for CRISPR and Cas9 delivery

Viral vectors represent one of the most effective platforms for delivering CRISPR-Cas9 components into mammalian cells, particularly for therapeutic gene editing in cancer¹¹. Among the most commonly utilized viral carriers are AAV, lentivirus, and adenovirus, each offering unique characteristics in terms of transduction efficiency, cargo capacity, immunogenicity, and genome integration⁶.

Adeno-associated virus vectors have emerged as popular candidates due to their low immunogenicity and ability to infect both dividing and non-dividing cells¹². However, their relatively small packaging capacity, approximately 4.7 kilobases, poses a major limitation, particularly when delivering the full-length *Streptococcus pyogenes* Cas9 (SpCas9) gene along with its associated guide RNA¹³. To circumvent this, alternative strategies as using smaller Cas9 orthologs such as *Staphylococcus aureus* Cas9 (SaCas9) or employing dual-vector systems have been explored¹².

Lentiviral vectors, derived from Human Immunodeficiency Virus-1 (HIV-1), offer a larger packaging capacity (~8 kb) and stable integration into the host genome, supporting long-term expression of Cas9 and gRNA¹⁴. While effective, the risk of insertional mutagenesis and oncogene activation has raised safety concerns, especially for therapeutic applications in humans¹⁴. Adenoviral vectors, on the other hand, do not integrate into the genome and provide a relatively large packaging capacity (up to ~36 kb), making them suitable for delivering full CRISPR systems¹⁵. Nevertheless, their high immunogenicity and potential to induce strong inflammatory responses present substantial challenges for clinical use¹⁵. Despite their differences, viral vectors share several advantages for CRISPR-Cas9 delivery. They exhibit high transduction efficiency and can be engineered for tissue-specific tropism, allowing for targeted delivery in tumors¹⁶. Lentiviral vectors, in particular, provide sustained gene expression that may be beneficial for prolonged gene editing in rapidly proliferating cancer cells¹⁷. Additionally, the possibility of pseudo-typing viral envelopes or modifying capsids opens avenues for selective targeting of tumor subtypes or specific niches within the tumor microenvironment¹⁶. However, these advantages must be weighed against inherent limitations¹⁶. Size constraints, particularly in AAV vectors, restrict the delivery of larger Cas9 variants or multiplexed gRNA arrays¹⁸. Immunogenicity remains a significant barrier, particularly for adenoviral vectors, which have been associated with systemic toxicity and rapid clearance. Moreover, genome-integrating vectors,

such as lentivirus, raise concerns regarding insertional mutagenesis and long-term safety¹⁹. Consequently, considerable efforts have been directed toward the development of next-generation viral systems, including non-integrating lentiviruses, self-deleting vectors, and engineered AAV capsids with enhanced packaging capacity and reduced immune recognition.

2.1. Evaluation in xenograft models

The performance of viral CRISPR-Cas9 delivery systems has been extensively evaluated in xenograft models, which remain the gold standard for *in vivo* validation in cancer gene therapy²⁰. Xenograft models, typically involving the implantation of human tumor cells into immunodeficient mice, offer an *in vivo* platform for assessing delivery efficiency, genome editing precision, therapeutic efficacy, and toxicity⁸. For example, AAV-mediated delivery of SaCas9 targeting E6/E7 oncogenes has demonstrated significant tumor suppression in cervical cancer xenografts, underscoring the potential of CRISPR-based viral systems in oncolytic gene therapy²¹. Similarly, lentiviral vectors encoding Cas9 and guide RNAs directed against oncogenic KRAS mutations have shown successful tumor growth inhibition in lung cancer models, particularly when combined with immunotherapy agents²². These results highlight the capacity of lentivirus to induce sustained genetic modulation *in vivo*, although risks associated with genomic integration persist (Figure 2).




Figure 2. Illustration of Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein 9 nanocarrier delivery in a xenograft mouse model. The figure depicts the intravenous administration of nanocarriers, their circulation and tumor-specific targeting, cellular uptake by human tumor cells engrafted in the mouse, endosomal escape, and release of the CRISPR-Cas9-sgRNA complex, resulting in targeted gene editing within the xenograft tumor tissue (Figure designed by Biorender).

Adenoviral vectors have also been used to deliver CRISPR-Cas9 for transient disruption of oncogenic signaling pathways in xenograft models of glioblastoma and hepatocellular carcinoma²³. While effective in inducing gene knockdown, these studies often report heightened immune cell infiltration and tissue damage, necessitating optimization of vector dose and delivery route to improve therapeutic windows²³. Overall, data from xenograft studies affirmed that viral vectors can achieve high genome editing efficiency and notable therapeutic outcomes. Nonetheless, limitations related to immunogenicity, off-target effects, and vector-induced toxicity remain significant hurdles to clinical translation. Continued engineering of viral carriers and refinement of delivery strategies in preclinical xenograft models are essential to balancing efficacy and safety in CRISPR-based oncolytic gene therapies²⁴.

3. Non-viral nano-carriers for CRISPR and Cas9 delivery

Non-viral nanocarriers have emerged as versatile and increasingly preferred alternatives to viral vectors for CRISPR-Cas9 delivery, particularly in the context of cancer gene therapy. Unlike viral systems, non-viral nanocarriers offer customizable physicochemical properties, reduced immunogenicity, and scalable production, which are especially important for clinical translation²⁵. Among the various types, LNP, polymeric nanoparticles, dendrimers, and inorganic nanomaterials have demonstrated significant promise in delivering CRISPR components with varying degrees of success in both *in vitro* and *in vivo* properties²⁶.

3.1. Lipid nanoparticles

Lipid nanoparticles are currently the most clinically advanced non-viral vectors, with successful application in mRNA vaccine platforms providing a translational precedent for gene-editing therapies²⁷. Lipid nanoparticles typically consist of ionizable lipids, helper lipids, cholesterol, and polyethylene glycol (PEG)-lipids, which together form a stable, biocompatible structure capable of encapsulating and protecting Cas9 mRNA, plasmids, or ribonucleoprotein (RNP) complexes²⁸. The efficiency of LNPs relies on protonation under endosomal pH, promoting endosomal escape and cytoplasmic release of cargo²⁹. Lipid nanoparticles have demonstrated effective delivery of CRISPR-Cas9 to hepatocytes, and more recently, to solid tumors through intratumoral or systemic administration²⁸. Advances in tumor-targeting strategies, such as ligand-functionalized LNPs, have improved their specificity toward cancer cells while minimizing off-target delivery to healthy tissues²⁸. Notably, the Food and Drug Administration-approved LNP-based siRNA drug, Patisiran, and mRNA vaccines have accelerated the clinical evaluation of LNPs for gene editing in cancer²⁹.

3.2. Polymeric nanoparticles

In addition to LNPs, polymeric nanoparticles have attracted attention due to their structural diversity and tunable degradation kinetics³⁰. Cationic polymers such as polyethyleneimine (PEI), poly lactic-co-glycolic acid

(PLGA), and chitosan have been employed to condense and deliver CRISPR plasmids or RNP³¹. While PEI provides efficient gene condensation and endosomal escape, it often exhibits cytotoxicity at higher molecular weights³². Poly lactic-co-glycolic acid, on the other hand, is FDA-approved and biodegradable, making it suitable for sustained delivery applications³². These polymers can be engineered to achieve controlled release, pH-responsive behavior, or surface functionalization with targeting ligands, thus enhancing tumor selectivity³³. Dendrimers, particularly polyamidoamine (PAMAM) dendrimers, offer precise control over molecular architecture and have demonstrated successful delivery of CRISPR components with relatively low toxicity and high cellular uptake³⁴.

3.3. Inorganic nanocarriers

Inorganic nanocarriers, such as gold nanoparticles, mesoporous silica nanoparticles, and magnetic nanoparticles, represent another class of non-viral delivery systems with distinct advantages³⁵. The rigidity of inorganic nanocarriers, ease of functionalization, and responsiveness to external stimuli (such as magnetic fields or light) allow for site-specific delivery and triggered release mechanisms³⁶. Gold nanoparticles, in particular, have been used to deliver CRISPR-Cas9 RNP into tumor cells with high precision and minimal toxicity, owing to their biocompatibility and ease of surface modification³⁷.

The performance of these non-viral nanocarriers has been rigorously evaluated in xenograft models to assess their gene-editing efficiency, safety, and biodistribution. In hepatocellular carcinoma xenografts, LNP carrying Cas9 mRNA and guide RNA targeting telomerase reverse transcriptase (TERT) or MYC have achieved significant tumor suppression, with minimal off-target effects and no overt toxicity³⁸. Similarly, PLGA-based nanoparticles loaded with CRISPR plasmids targeting programmed cell death ligand 1 (PD-L1) or vascular endothelial growth factor (VEGF) have demonstrated robust anti-tumor effects in breast and colon cancer xenografts, often accompanied by increased immune cell infiltration and vascular normalization³⁹. Dendrimer-based systems have shown efficient knockdown of oncogenes such as BCL2 and EZH2 in lymphoma and glioblastoma models, indicating their potential for targeting diverse tumor types⁴⁰.

Inorganic nanoparticles, particularly gold-based systems, have enabled tumor-specific delivery of CRISPR-Cas9 in xenograft models of ovarian and prostate cancer⁴¹. These platforms often incorporate tumor-targeting peptides or aptamers to enhance selectivity. Importantly, they enable real-time tracking via imaging modalities, providing a theranostic advantage⁴¹. Across these studies, non-viral carriers have consistently demonstrated favorable safety profiles, with low systemic toxicity, minimal immunogenicity, and efficient tumor accumulation, particularly when administered via localized routes or combined with tumor-penetrating agents²⁶. Collectively, non-viral nanocarriers provide a flexible and safe

alternative for CRISPR-Cas9 delivery in oncolytic gene therapy. Non-viral nanocarriers' adaptability in surface chemistry, cargo loading, and release profiles enables precise tuning for specific tumor environments. Data from xenograft models support their efficacy and biocompatibility, underscoring their potential for clinical advancement in cancer genome editing⁸⁻¹⁰.

4. Comparative assessment of viral and non-viral CRISPR and Cas9 delivery in xenograft models

A critical aspect in the development of CRISPR-Cas9-based oncolytic gene therapies lies in the choice of an appropriate delivery vehicle⁴². Viral and non-viral nanocarriers differ markedly in their efficiency, safety, and translational potential⁴². A comparative analysis of these platforms, particularly in xenograft models, provides key insights into their respective advantages and limitations (Table 1).

In terms of delivery efficiency, viral vectors generally outperform non-viral systems⁴². Lentiviral and adenoviral vectors exhibit high transduction rates in both *in vitro* and *in vivo* settings, achieving genome editing efficiencies exceeding 70% in some tumor xenograft models⁴³. Their innate ability to penetrate the nuclear envelope and integrate or transiently express CRISPR-Cas9 components contributes to their superior performance⁴⁴. Adeno-associated viruses' vectors, despite their limited cargo capacity, have demonstrated efficient delivery in liver and muscle tissues, especially when using compact Cas9 variants or dual-vector systems⁴⁵. In contrast, non-viral systems such as LNP and polymeric carriers typically indicate moderate delivery efficiency, often limited by endosomal entrapment or insufficient intracellular trafficking⁴⁶. However, recent advances in ionizable lipid formulations, surface modifications, and tumor-targeting ligands have significantly improved the delivery performance of LNP, narrowing the gap with viral systems in certain contexts⁴⁷.

Table 1. Comparative summary of viral and non-viral clustered regularly interspaced short palindromic repeats (CRISPR) delivery systems

Feature	Viral vectors (AAV, Lentivirus)	Non-viral nanocarriers (LNP, Polymers)
Delivery efficiency	High (especially in dividing cells)	Moderate to high (improving with newer systems)
Packaging capacity	Limited (especially AAV: ~4.7 kb)	Flexible (can accommodate large constructs)
Immunogenicity	Moderate to high	Typically, lower
Integration risk	Possible (lentivirus)	No genome integration
Scalability and GMP	Complex, costly	Easier to scale, more industrial-friendly
Targeting flexibility	Genetically engineered	Tunable via surface chemistry
Clinical maturity	Several in clinical trials	Gaining traction in recent years

AAV: Adeno-associated viruses; LNP: Lipid nanoparticles; GMP: Good manufacturing practice

Safety and biocompatibility represent a major strength of non-viral nanocarriers⁴⁸. Viral vectors, especially adenovirus and lentivirus, are associated with immunogenicity, inflammation, and potential risks of insertional mutagenesis⁴⁹. These concerns are particularly critical in therapeutic settings where long-term gene expression is not required or could be detrimental⁴⁹. While AAV are generally considered safer due to their low immunogenic profile and episomal nature, they can still elicit neutralizing antibody responses, particularly upon repeated administration⁵⁰. Non-viral nanocarriers, on the other hand, offer minimal immunogenicity and reduced systemic toxicity⁷. Lipid nanoparticles and polymer-based systems have demonstrated favorable safety profiles in both preclinical and clinical settings, with transient expression and rapid clearance reducing the risk of off-target or long-term effects^{33,34,47}. Additionally, non-viral systems allow for greater control over dose and release kinetics, which can be tailored to the tumor microenvironment⁴⁹.

Comparative studies in xenograft models have highlighted the trade-offs between efficacy and safety in these two delivery strategies. For instance, in glioblastoma and hepatocellular carcinoma xenografts, lentiviral and adenoviral vectors achieved rapid tumor regression through efficient CRISPR-mediated knockdown of driver oncogenes^{23,38}. However, these effects were often accompanied by vector-induced inflammation or off-target

genome edits. In parallel models, non-viral carriers such as polyethylene glycolylated LNPs or PLGA-based nanoparticles induced more gradual tumor inhibition but showed lower levels of systemic cytokine release and organ toxicity⁵¹. Notably, in previous studies targeting the same gene, such as *Kirsten rat sarcoma viral oncogene homologue* (KRAS) or PD-L1, viral systems have produced higher editing rates, while non-viral platforms have provided better safety and repeatability⁵².

The choice between the viral and non-viral delivery often depends on the therapeutic context⁴³. For applications requiring high editing efficiency in a short timeframe, such as aggressive, rapidly progressing tumors, viral vectors may be preferable, provided immune responses are manageable⁴². In contrast, for chronic conditions, immunologically sensitive sites, or combination therapies involving repeated dosing, non-viral nanocarriers offer a more favorable safety profile^{46,47}. Emerging hybrid systems that combine the strengths of both platforms, such as virus-like particles (VLP) or biomimetic nanocarriers, are currently under investigation and may bridge the gap between efficiency and biocompatibility⁵³. Ultimately, data from xenograft models underscore that while viral vectors currently lead in raw efficiency, non-viral carriers hold strong potential for safe, modular, and clinically adaptable CRISPR-Cas9 delivery⁵⁴. A rational, case-specific selection of delivery modality guided by tumor biology, therapeutic goals, and safety

considerations is essential for advancing genome-editing-based cancer therapies toward clinical reality⁵⁴.

5. Clinical applications and emerging challenges in CRISPR-based oncolytic therapy

The translation of CRISPR-Cas9 technology into clinical applications has marked a significant turning point in the field of oncology, especially within the context of precision and oncolytic gene therapies⁵⁵. This gene-editing system offers a powerful platform for reprogramming cancer cells, modulating immune responses, and enhancing viral oncolytic strategies in a highly specific and controllable manner. While still in early stages of clinical development, CRISPR-Cas9 has already begun to redefine the boundaries of what is therapeutically possible in cancer treatment⁵⁵.

One of the most compelling roles of CRISPR-Cas9 in cancer therapy is its capacity to enable direct, sequence-specific targeting of oncogenic mutations⁵⁶. Unlike conventional treatments that often affect both cancerous and healthy cells, CRISPR allows for the knockout or correction of driver mutations such as KRAS^{G12D}, TP53^{mut}, or BRAF^{V600E}, which are critical for tumor survival and proliferation⁵⁵. In xenograft and organoid models, targeted disruption of these genes has led to significant tumor regression, providing proof-of-concept for precision genome editing as a viable therapeutic approach^{8,9}. Additionally, CRISPR has been applied to disrupt genes responsible for drug resistance, such as ATP-binding cassette (ABC) transporters or DNA repair enzymes, thereby sensitizing tumors to chemotherapy or radiotherapy⁵⁷.

Beyond editing cancer cell genomes, CRISPR is being used to engineer immune effector cells for more potent anti-tumor responses⁵⁸. In particular, CRISPR-modified T cells have been employed to knock out checkpoint inhibitory genes such as PD-1, Cytotoxic T lymphocyte antigen-4 (CTLA-4), or lymphocyte activation gene 3 (LAG-3), resulting in enhanced tumor cell killing and improved persistence *in vivo*⁵⁸. These next-generation *Chimeric antigen receptor* (CAR-T) cells, often referred to as "armored" CAR-Ts, have demonstrated superior efficacy in preclinical models of solid tumors, which historically have been resistant to conventional T cell therapies^{1,2,59}. In one notable clinical study, CRISPR was used to simultaneously knock out endogenous *T-cell receptor* (TCR) and PD-1 in patient-derived T cells, leading to safe expansion and detectable tumor infiltration post-infusion⁶⁰⁻⁶³. Such multiplex editing would be nearly impossible with earlier gene-editing tools, underscoring the versatility of the CRISPR system⁶². However, as CRISPR entered clinical pipelines, several safety and immunological concerns have surfaced that must be carefully addressed. Off-target effects remain one of the most frequently cited risks, wherein CRISPR induces unintended cuts at loci that resemble the target sequence^{58,64-66}. Such edits can lead to genomic instability, disruption of tumor suppressors, or activation of proto-oncogenes, with potentially oncogenic

consequences⁵⁸. Although high-fidelity Cas9 variants (such as eSpCas9, SpCas9-HF1) and improved sgRNA design algorithms have significantly reduced these effects, the risk cannot be entirely eliminated⁵⁹. Moreover, strategies such as delivery of Cas9 as a transient RNP complex and limiting exposure duration are being employed to further enhance genome editing precision⁶⁷⁻⁶⁹.

The Cas9 is derived from bacterial species and can trigger both innate and adaptive immune responses in humans, particularly if administered systemically or repeatedly⁷⁰. Pre-existing antibodies and T cell responses against Cas9 have already been detected in a significant proportion of the population⁷¹. This can lead to rapid clearance of CRISPR components or, worse, severe immune-mediated toxicity. To overcome this issue, efforts are underway to develop orthologous Cas nucleases from less common bacteria and to refine Cas9 proteins for improved compatibility with human systems, or encapsulate them within stealth nanocarriers that shield them from immune surveillance⁷¹.

In the context of delivery, both viral and non-viral platforms face translational challenges. Viral vectors offer efficient gene delivery but raise concerns regarding immunogenicity, genome integration, and limited cargo capacity⁷². Non-viral systems, while safer and more flexible, often suffer from suboptimal delivery efficiency, especially in hard-to-reach solid tumors^{6,7}. As a result, new strategies are being developed to combine the best aspects of both systems. These include virus-like particles (VLPs), cell membrane-coated nanoparticles, and extracellular vesicle-based delivery platforms capable of delivering CRISPR-Cas9 in a tumor-specific and immune-evasive manner⁷³.

The therapeutic landscape is also evolving through the integration of CRISPR with other modalities. Combination therapies that pair CRISPR-based genome editing with immune checkpoint inhibitors, oncolytic viruses, or epigenetic drugs are gaining traction^{74,75}. For instance, knocking out PD-L1 in tumor cells using CRISPR has been shown to enhance the efficacy of anti-PD-1 antibodies in immunocompetent mouse models⁶². Similarly, CRISPR can be used to disable genes encoding immune-suppressive cytokines such as TGF- β in the tumor microenvironment, thereby amplifying the host immune response². In an emerging approach, CRISPR is being employed to genetically engineer oncolytic viruses, enhancing their tumor selectivity and replication kinetics to develop more potent and programmable virotherapeutics⁷⁶.

Looking forward, several trends are likely to shape the future of CRISPR-based oncolytic therapies⁷⁷. These therapies include the development of inducible or self-regulating CRISPR systems, which enable gene editing to be turned on or off in response to external stimuli, such as light, temperature, or small molecules⁷⁷. Another exciting area in genome-editing technologies is the use of base editors and prime editing systems, which allow for precise nucleotide changes without inducing double-stranded DNA breaks, thus minimizing DNA damage and off-target mutations⁷⁷. Patient-specific xenograft and organoid models are also being leveraged to tailor CRISPR treatments to individual

tumors, advancing the promise of personalized medicine².

While considerable progress has been made, CRISPR-based cancer therapies are still at a formative stage, with only a handful of clinical trials completed and most others in early phases¹³. Regulatory oversight, manufacturing scalability, ethical considerations (particularly for germline editing), and cost-effectiveness will all play crucial roles in determining how broadly these therapies are adopted in clinical practice¹³. Thus, CRISPR-Cas9 represents a paradigm shift in cancer therapy, offering unmatched precision, programmability, and potential for synergy with existing and emerging treatments. With careful optimization of delivery systems, rigorous preclinical validation, and robust safety profiling, CRISPR is poised to become a cornerstone technology in the next generation of oncolytic and personalized cancer therapies⁵⁶.

6. Regulatory and ethical considerations in CRISPR-based oncolytic therapies

As CRISPR-Cas9 technology progresses from preclinical success toward clinical implementation in cancer therapy, regulatory and ethical considerations become increasingly critical⁵⁵. Unlike traditional small-molecule drugs or biologics, genome editing introduces permanent changes to the genetic material of target cells, raising unique safety, legal, and moral questions⁵⁶. These concerns are particularly relevant in oncolytic applications, where therapeutic interventions are intended to selectively destroy malignant cells but may interact unpredictably with host immunity, non-tumor tissues, or the broader tumor microenvironment⁵⁵.

From a regulatory standpoint, the delivery system used for CRISPR components plays a pivotal role in risk assessment and approval pathways⁷⁸. Viral vectors such as AAV and lentivirus, despite their delivery efficiency, carry risks of insertional mutagenesis and long-term expression of foreign proteins, which must be rigorously evaluated through toxicology and biodistribution studies⁷². Non-viral nanocarriers, although perceived as safer, are not exempt from scrutiny, particularly when they incorporate synthetic polymers or metallic cores that may elicit immunogenic or off-target effects⁶. Regulatory bodies such as the U.S. food and drug administration (FDA) and European medicines agency (EMA) now require detailed characterization of nanocarrier properties, pharmacokinetics, and potential off-target editing before approving CRISPR-based therapies for clinical trials⁷⁹.

Another core issue is the long-term follow-up of patients treated with gene-editing interventions. Unlike conventional chemotherapies, CRISPR-based therapies may induce durable or even irreversible changes, necessitating decades-long monitoring for potential delayed effects such as secondary malignancies, genotoxicity, or unintended immune consequences⁸⁰. This need for extended surveillance poses practical and financial challenges for clinical trial design and patient consent.

Ethically, one of the most debated topics surrounding CRISPR is the boundary between somatic and germline

editing⁸¹. While current cancer therapies target only somatic cells, concerns remain about inadvertent germline modifications, particularly when CRISPR is delivered systemically or through viral vectors with broad tropism^{82,83}. Even in somatic contexts, questions about patient autonomy, informed consent, and equitable access to emerging therapies remain unresolved⁸². Vulnerable populations, such as those with aggressive or rare cancers, may feel pressured to enroll in early-stage trials with uncertain outcomes, raising the risk of therapeutic misconception. Furthermore, disparities in global regulatory frameworks can create ethical gray zones. For example, some countries may fast-track CRISPR trials without robust oversight, potentially leading to premature clinical use or exploitation of patients⁸¹. Developing unified international guidelines that effectively balance innovation and patient safety remains a pressing priority. Organizations such as the international society for cell and gene therapy (ISCT) and the world health organization (WHO) have begun developing ethical governance models, but consistent enforcement remains a challenge⁸⁴. In addition to regulatory reform, there is a growing call for broader societal dialogue around genome editing⁸⁰. Public trust in CRISPR-based cancer therapies will depend not only on clinical efficacy but also on transparent communication, ethical oversight, and responsible innovation⁸⁰. Incorporating patient perspectives, engaging bioethicists, and fostering interdisciplinary collaboration among scientists, clinicians, and policymakers is crucial to guiding CRISPR technologies toward safe and just clinical integration^{78,79}. In conclusion, CRISPR-based oncolytic therapies offer great potential, but their safe and ethical implementation in clinical settings necessitates strong regulatory frameworks, long-term patient monitoring, and continuous ethical discussions. Proactively addressing these aspects is crucial to responsibly fulfill the promise of gene editing equitably.

7. Conclusion

CRISPR-Cas9-based cancer therapy has advanced significantly, with viral and non-viral nanocarriers improving targeted delivery. Preclinical xenograft models, particularly patient-derived xenografts, are crucial for evaluating efficacy and safety, bridging lab research and clinical trials. Key findings highlighted that the importance of delivery systems, optimal tumor penetration, immune evasion, and controlled cargo release are essential for therapeutic success, specifically, achieving efficient tumor regression while minimizing off-target effects and systemic toxicity. Next-generation strategies include ligand-functionalized nanoparticles for precise targeting, stimuli-responsive carriers for tumor-specific release, and RNP delivery to reduce immune reactions and genomic instability. Challenges remain, such as the immunogenicity of Cas proteins and delivery vectors. Solutions under exploration include less immunogenic Cas variants and exosome-based carriers. Additionally, tumor heterogeneity demands adaptable, patient-specific systems.

Future progress hinges on the integration of

nanotechnology, synthetic biology, and personalized medicine. Multifunctional nanocarriers that co-deliver CRISPR with immunotherapies or diagnostics could enhance precision. Emerging tools such as base and prime editors will require advanced delivery platforms. Ultimately, the clinical success of CRISPR-based cancer therapy depends on combining precise gene editing with safe, efficient delivery. By leveraging insights from xenograft models, particularly patient-derived xenografts and cell-line-derived xenografts, and innovations in nanocarriers, personalized genome-targeted treatments are approaching reality. Interdisciplinary collaboration will be essential for overcoming remaining challenges.

Declarations

Authors' contributions

Mehran Bahmani wrote the draft of the manuscript, editing and finalization the paper. The author has read and approved the final version of the manuscript before publication in the present journal.

Availability of data and materials

The data to support the present study finding is available upon reasonable request to the corresponding author.

Competing interests

The author had no conflict of interest.

Ethical considerations

The author has reviewed all ethical problems, including plagiarism, consent to publish, data fabrication, and falsification.

Funding

The authors declare that no funding sources supported the present study.

References

- Garcia-Robledo JE, Barrera MC, and Tobón GJ. CRISPR/Cas: from adaptive immune system in prokaryotes to therapeutic weapon against immune-related diseases. *Int Rev Immunol*. 2020; 39(1): 11-20. DOI: [10.1080/08830185.2019.1677645](https://doi.org/10.1080/08830185.2019.1677645)
- Lotfalizadeh N, Sadr S, Simab PA, Hajjafari A, Borji H, and Bayat Z. CRISPR/Cas9-mediated genome editing: In vivo review. *J Lab Anim Res*. 2022; 1(1): 47-51. DOI: [10.58803/jlar.v1i1.13](https://doi.org/10.58803/jlar.v1i1.13)
- Kirchner M, and Schneider S. CRISPR-Cas: from the bacterial adaptive immune system to a versatile tool for genome engineering. *Angew Chem Int Ed*. 2015; 54(46): 13508-13514. DOI: [10.1002/anie.201504741](https://doi.org/10.1002/anie.201504741)
- Luther DC, Lee YW, Nagaraj H, Scaletti F, and Rotello VM. Delivery approaches for CRISPR/Cas9 therapeutics in vivo: advances and challenges. *Expert Opin Drug Deliv*. 2018; 15(9): 905-913. DOI: [10.1080/17425247.2018.1517746](https://doi.org/10.1080/17425247.2018.1517746)
- Foley RA, Sims RA, Duggan EC, Olmedo JK, Ma R, and Jonas SJ. Delivering the CRISPR/Cas9 system for engineering gene therapies: Recent cargo and delivery approaches for clinical translation. *Front Bioeng Biotechnol*. 2022; 10: 973326. DOI: [10.3389/fbioe.2022.973326](https://doi.org/10.3389/fbioe.2022.973326)
- Nayerossadat N, Maedeh T, and Ali PA. Viral and nonviral delivery systems for gene delivery. *Adv Biomed Res*. 2012; 1(1): 27. DOI: [10.4103/2277-9175.98152](https://doi.org/10.4103/2277-9175.98152)
- Patil S, Gao YG, Lin X, Li Y, Dang K, Tian Y, et al. The development of functional non-viral vectors for gene delivery. *Int J Mol Sci*. 2019; 20(21): 5491. DOI: [10.3390/ijms20215491](https://doi.org/10.3390/ijms20215491)
- Taha EA, Lee J, and Hotta A. Delivery of CRISPR-Cas tools for in vivo genome editing therapy: Trends and challenges. *J Control Release*. 2022; 342: 345-361. DOI: [10.1016/j.jconrel.2022.01.013](https://doi.org/10.1016/j.jconrel.2022.01.013)
- Behr M, Zhou J, Xu B, and Zhang H. In vivo delivery of CRISPR-Cas9 therapeutics: Progress and challenges. *Acta Pharm Sin B*. 2021; 11(8): 2150-2171. DOI: [10.1016/j.apsb.2021.05.020](https://doi.org/10.1016/j.apsb.2021.05.020)
- Liu Y, Wu W, Cai C, Zhang H, Shen H, and Han Y. Patient-derived xenograft models in cancer therapy: technologies and applications. *Signal Transduct Target Ther*. 2023; 8(1): 160. DOI: [10.1038/s41392-023-01419-2](https://doi.org/10.1038/s41392-023-01419-2)
- Xu X, Wan T, Xin H, Li D, Pan H, Wu J, et al. Delivery of CRISPR/Cas9 for therapeutic genome editing. *J Gene Med*. 2019; 21(7): e3107. DOI: [10.1002/jgm.3107](https://doi.org/10.1002/jgm.3107)
- Biagioni A, Laurenzana A, Margheri F, Chillà A, Fibbi G, and Del Rosso M. Delivery systems of CRISPR/Cas9-based cancer gene therapy. *J Biol Eng*. 2018; 12: 1-9. DOI: [10.1186/s13036-018-0127-2](https://doi.org/10.1186/s13036-018-0127-2)
- Sadr S, Ahmadi Simab P, and Borji H. CRISPR-Cas9 as a Potential Cancer Therapy Agent: An Update. *Res Biotechnol Environ Sci*. 2023; 2(1): 12-17. DOI: [10.58803/RBES.2023.2.1.02](https://doi.org/10.58803/RBES.2023.2.1.02)
- Johnson NM, Alvarado AF, Moffatt TN, Edavettal JM, Swaminathan TA, and Braun SE. HIV-based lentiviral vectors: Origin and sequence differences. *Mol Ther Methods Clin Dev*. 2021; 21: 451-465. DOI: [10.1016/j.omtm.2021.03.018](https://doi.org/10.1016/j.omtm.2021.03.018)
- Ahmadi SE, Soleymani M, Shahriyari F, Amirzargar MR, Ofoghi M, Fattahi MD, et al. Viral vectors and extracellular vesicles: innate delivery systems utilized in CRISPR/Cas-mediated cancer therapy. *Cancer Gene Ther*. 2023; 30(7): 936-954. DOI: [10.1038/s41417-023-00597-z](https://doi.org/10.1038/s41417-023-00597-z)
- Xu CL, Ruan MZ, Mahajan VB, and Tsang SH. Viral delivery systems for CRISPR. *Viruses*. 2019; 11(1): 28. DOI: [10.3390/v11010028](https://doi.org/10.3390/v11010028)
- Mengstie MA. Viral vectors for the in vivo delivery of CRISPR components: Advances and challenges. *Front Bioeng Biotechnol*. 2022; 10: 895713. DOI: [10.3389/fbioe.2022.895713](https://doi.org/10.3389/fbioe.2022.895713)
- Chandrasekaran AP, Song M, Kim KS, and Ramakrishna S. Different methods of delivering CRISPR/Cas9 into cells. *Prog Mol Biol Transl Sci*. 2018; 159: 157-176. DOI: [10.1016/bs.pmbts.2018.05.001](https://doi.org/10.1016/bs.pmbts.2018.05.001)
- Yang W, Yan J, Zhuang P, Ding T, Chen Y, Zhang Y, et al. Progress of delivery methods for CRISPR-Cas9. *Expert Opin Drug Deliv*. 2022; 19(8): 913-926. DOI: [10.1080/17425247.2022.2100342](https://doi.org/10.1080/17425247.2022.2100342)
- Song M. The CRISPR/Cas9 system: Their delivery, in vivo and ex vivo applications, and clinical development by startups. *Biotechnol Prog*. 2017; 33(4): 1035-1045. DOI: [10.1002/btpr.2484](https://doi.org/10.1002/btpr.2484)
- Wang D, Zhang F, and Gao G. CRISPR-based therapeutic genome editing: Strategies and in vivo delivery by AAV vectors. *Cell*. 2020; 181(1): 136-150. DOI: [10.1016/j.cell.2020.03.023](https://doi.org/10.1016/j.cell.2020.03.023)
- Singh D. Revolutionizing Lung Cancer Treatment: Innovative CRISPR-Cas9 Delivery Strategies. *AAPS PharmSciTech*. 2024; 25(5): 129. DOI: [10.1208/s12249-024-02834-6](https://doi.org/10.1208/s12249-024-02834-6)
- Nie JJ, Liu Y, Qi Y, Zhang N, Yu B, Chen DF, et al. Charge-reversal nanocomplexes-based CRISPR/Cas9 delivery system for loss-of-function oncogene editing in hepatocellular carcinoma. *J Control Release*. 2021; 333: 362-373. DOI: [10.1016/j.jconrel.2021.03.030](https://doi.org/10.1016/j.jconrel.2021.03.030)
- Yi K, Kong H, Lao YH, Li D, Mintz RL, Fang T, et al. Engineered nanomaterials to potentiate CRISPR/Cas9 gene editing for cancer therapy. *Adv Mater*. 2024; 36(13): 2300665. DOI: [10.1002/adma.202300665](https://doi.org/10.1002/adma.202300665)
- Lin YQ, Feng KK, Lu JY, Le JQ, Li WL, Zhang BC, et al. CRISPR/Cas9-based application for cancer therapy: Challenges and solutions for non-viral delivery. *J Control Release*. 2023; 361: 727-749. DOI: [10.1016/j.jconrel.2023.08.028](https://doi.org/10.1016/j.jconrel.2023.08.028)
- Jiang Y, Fan M, Yang Z, Liu X, Xu Z, Liu S, et al. Recent advances in nanotechnology approaches for non-viral gene therapy. *Biomater Sci*. 2022; 10(24): 6862-6892. DOI: [10.1039/D2BM01001A](https://doi.org/10.1039/D2BM01001A)
- Masarwy R, Stotsky-Oterin L, Elisha A, Hazan-Halevy I, and Peer D. Delivery of nucleic acid based genome editing platforms via lipid nanoparticles: Clinical applications. *Adv Drug Deliv Rev*. 2024; 211: 115555. DOI: [10.1016/j.addr.2024.115555](https://doi.org/10.1016/j.addr.2024.115555)

115359. DOI: [10.1016/j.addr.2024.115359](https://doi.org/10.1016/j.addr.2024.115359)
28. Li X, Qi J, Wang J, Hu W, Zhou W, Wang Y, et al. Nanoparticle technology for mRNA: Delivery strategy, clinical application and developmental landscape. *Theranostics*. 2024; 14(2): 738-758. DOI: [10.7150/thno.84291](https://doi.org/10.7150/thno.84291)
29. Yang L, Gong L, Wang P, Zhao X, Zhao F, Zhang Z, et al. Recent advances in lipid nanoparticles for delivery of mRNA. *Pharmaceutics*. 2022; 14(12): 2682. DOI: [10.3390/pharmaceutics14122682](https://doi.org/10.3390/pharmaceutics14122682)
30. Kamaly N, Yameen B, Wu J, and Farokhzad OC. Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release. *Chem Rev*. 2016; 116(4): 2602-2663. DOI: [10.1021/acs.chemrev.5b00346](https://doi.org/10.1021/acs.chemrev.5b00346)
31. Kumar AP, Depan D, Tomer NS, and Singh RP. Nanoscale particles for polymer degradation and stabilization-trends and future perspectives. *Prog Polym Sci*. 2009; 34(6): 479-515. DOI: [10.1016/j.progpolymsci.2009.01.002](https://doi.org/10.1016/j.progpolymsci.2009.01.002)
32. Beach MA, Nayanathara U, Gao Y, Zhang C, Xiong Y, Wang Y, et al. Polymeric nanoparticles for drug delivery. *Chem Rev*. 2024; 124(9): 5505-5616. DOI: [10.1021/acs.chemrev.3c00705](https://doi.org/10.1021/acs.chemrev.3c00705)
33. Banik BL, Fattahi P, and Brown JL. Polymeric nanoparticles: the future of nanomedicine. *Wiley Interdiscip Rev Nanomed Nanobiotechnol*. 2016; 8(2): 271-299. DOI: [10.1002/wnan.1364](https://doi.org/10.1002/wnan.1364)
34. Rai R, Alwani S, and Badea I. Polymeric nanoparticles in gene therapy: New avenues of design and optimization for delivery applications. *Polymers*. 2019; 11(4): 745. DOI: [10.3390/polym11040745](https://doi.org/10.3390/polym11040745)
35. Aljabali AA, and Obeid MA. Inorganic-organic nanomaterials for therapeutics and molecular imaging applications. *Nanosci Nanotechnol Asia*. 2020; 10(6): 748-765. DOI: [10.2174/2210681209666190807145229](https://doi.org/10.2174/2210681209666190807145229)
36. Chen S, Hao X, Liang X, Zhang Q, Zhang C, Zhou G, et al. Inorganic nanomaterials as carriers for drug delivery. *J Biomed Nanotechnol*. 2016; 12(1): 1-27. DOI: [10.1166/jbn.2016.2122](https://doi.org/10.1166/jbn.2016.2122)
37. Ali I, Mukhtar SD, Lone MN, Ali HS, and Aboul-Enein HY. Recent advances in mesoporous silica and gold based nanovectors in anticancer drug delivery system. *Curr Org Chem*. 2017; 21(23): 2400-2415. DOI: [10.2174/1385272820666161025161853](https://doi.org/10.2174/1385272820666161025161853)
38. Palaz F, Ozsoz M, Zarrinpar A, and Sahin I. CRISPR in targeted therapy and adoptive T cell immunotherapy for hepatocellular carcinoma. *J Hepatocell Carcinoma*. 2024; 11: 975-995. DOI: [10.2147/JHC.S456683](https://doi.org/10.2147/JHC.S456683)
39. Sun R, Chen Y, Pei Y, Wang W, Zhu Z, Zheng Z, et al. The drug release of PLGA-based nanoparticles and their application in treatment of gastrointestinal cancers. *Heliyon*. 2024; 10(18): e38165. DOI: [10.1016/j.heliyon.2024.e38165](https://doi.org/10.1016/j.heliyon.2024.e38165)
40. Fana M, Gallien J, Srinageshwar B, Dunbar GL, and Rossignol J. PAMAM dendrimer nanomolecules utilized as drug delivery systems for potential treatment of glioblastoma: A systematic review. *Int J Nanomedicine*. 2020; 15: 2789-2808. DOI: [10.2147/IJN.S243155](https://doi.org/10.2147/IJN.S243155)
41. Luo R, Le H, Wu Q, and Gong C. Nanoplatform-based in vivo gene delivery systems for cancer therapy. *Small*. 2024; 20(30): 2312153. DOI: [10.1002/sml.202312153](https://doi.org/10.1002/sml.202312153)
42. Taghdiri M, and Mussolino C. Viral and non-viral systems to deliver gene therapeutics to clinical targets. *Int J Mol Sci*. 2024; 25(13): 7333. DOI: [10.3390/ijms25137333](https://doi.org/10.3390/ijms25137333)
43. Dogbey DM, Torres VE, Fajemisin E, Mpondo L, Ngwenya T, Akinrinmade OA, et al. Technological advances in the use of viral and non-viral vectors for delivering genetic and non-genetic cargos for cancer therapy. *Drug Deliv Transl Res*. 2023; 13(11): 2719-2738. DOI: [10.1007/s13346-023-01362-3](https://doi.org/10.1007/s13346-023-01362-3)
44. Chen Q, Yu T, Gong J, and Shan H. Advanced nanomedicine delivery systems for cardiovascular diseases: Viral and non-viral strategies in targeted therapy. *Molecules*. 2025; 30(4): 962. DOI: [10.3390/molecules30040962](https://doi.org/10.3390/molecules30040962)
45. Mahato M, Jayandharan GR, and Vemula PK. Viral-and non-viral-based hybrid vectors for gene therapy. In: Jayandharan G, editor. *Gene and cell therapy: Biology and applications*. Springer; Singapore: 2018. p. 111-130. DOI: [10.1007/978-981-13-0481-1_4](https://doi.org/10.1007/978-981-13-0481-1_4)
46. Yan Y, Liu XY, Lu A, Wang XY, Jiang LX, and Wang JC. Non-viral vectors for RNA delivery. *J Control Release*. 2022; 342: 241-279. DOI: [10.1016/j.jconrel.2022.01.008](https://doi.org/10.1016/j.jconrel.2022.01.008)
47. Zong Y, Lin Y, Wei T, and Cheng Q. Lipid nanoparticle (LNP) enables mRNA delivery for cancer therapy. *Adv Mater*. 2023; 35(51): 2303261. DOI: [10.1002/adma.202303261](https://doi.org/10.1002/adma.202303261)
48. Zu H and Gao D. Non-viral vectors in gene therapy: Recent development, challenges, and prospects. *AAPS J*. 2021; 23(4): 78. DOI: [10.1208/s12248-021-00608-7](https://doi.org/10.1208/s12248-021-00608-7)
49. Ren S, Wang M, Wang C, Wang Y, Sun C, Zeng Z, et al. Application of non-viral vectors in drug delivery and gene therapy. *Polymers*. 2021; 13(19): 3307. DOI: [10.3390/polym13193307](https://doi.org/10.3390/polym13193307)
50. Suoranta T, Laham-Karam N, and Ylä-Herttuala S. Strategies to improve safety profile of AAV vectors. *Front Mol Med*. 2022; 2: 1054069. DOI: [10.3389/fmmed.2022.1054069](https://doi.org/10.3389/fmmed.2022.1054069)
51. Yoo YJ, Lee CH, Park SH, and Lim YT. Nanoparticle-based delivery strategies of multifaceted immunomodulatory RNA for cancer immunotherapy. *J Control Release*. 2022; 343: 564-583. DOI: [10.1016/j.jconrel.2022.01.047](https://doi.org/10.1016/j.jconrel.2022.01.047)
52. Vats S, Ballesteros C, Hung S, Sparapani S, Wong K, Haruna J, et al. An overview of gene editing modalities and related non-clinical testing considerations. *Int J Toxicol*. 2023; 42(3): 207-218. DOI: [10.1177/10915818231153996](https://doi.org/10.1177/10915818231153996)
53. Sun X, Tian T, Lian Y, and Cui Z. Current advances in viral nanoparticles for biomedicine. *ACS Nano*. 2024; 18(50): 33827-33863. DOI: [10.1021/acsnano.4c13146](https://doi.org/10.1021/acsnano.4c13146)
54. Song Z, Tao Y, Liu Y, and Li J. Advances in delivery systems for CRISPR/Cas-mediated cancer treatment: A focus on viral vectors and extracellular vesicles. *Front Immunol*. 2024; 15: 1444437. DOI: [10.3389/fimmu.2024.1444437](https://doi.org/10.3389/fimmu.2024.1444437)
55. Chira S, Nutu A, Isacescu E, Bica C, Pop L, Ciocan C, et al. Genome editing approaches with CRISPR/Cas9 for cancer treatment: Critical appraisal of preclinical and clinical utility, challenges, and future research. *Cells*. 2022; 11(18): 2781. DOI: [10.3390/cells11182781](https://doi.org/10.3390/cells11182781)
56. Uddin F, Rudin CM, and Sen T. CRISPR gene therapy: applications, limitations, and implications for the future. *Front Oncol*. 2020; 10: 1387. DOI: [10.3389/fonc.2020.01387](https://doi.org/10.3389/fonc.2020.01387)
57. Hou J, He Z, Liu T, Chen D, Wang B, Wen Q, et al. Evolution of molecular targeted cancer therapy: Mechanisms of drug resistance and novel opportunities identified by CRISPR-Cas9 screening. *Front Oncol*. 2022; 12: 755053. DOI: [10.3389/fonc.2022.755053](https://doi.org/10.3389/fonc.2022.755053)
58. Chen C, Wang Z, and Qin Y. CRISPR/Cas9 system: Recent applications in immuno-oncology and cancer immunotherapy. *Exp Hematol Oncol*. 2023; 12(1): 95. DOI: [10.1186/s40164-023-00457-4](https://doi.org/10.1186/s40164-023-00457-4)
59. Mollanoori H, Shahraki H, Rahmati Y, and Teimourian S. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment. *Hum Immunol*. 2018; 79(12): 876-882. DOI: [10.1016/j.humimm.2018.09.007](https://doi.org/10.1016/j.humimm.2018.09.007)
60. Razeghian E, Nasution MK, Rahman HS, Gardanova ZR, Abdelbasset WK, Aravindhan S, et al. A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies. *Stem Cell Res Ther*. 2021; 12: 1-7. DOI: [10.1186/s13287-021-02510-7](https://doi.org/10.1186/s13287-021-02510-7)
61. Liu X, Zhang Y, Cheng C, Cheng AW, Zhang X, Li N, et al. CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells. *Cell Res*. 2017; 27(1): 154-157. DOI: [10.1038/cr.2016.142](https://doi.org/10.1038/cr.2016.142)
62. Wei W, Chen ZN, and Wang K. CRISPR/Cas9: A powerful strategy to improve CAR-T cell persistence. *Int J Mol Sci*. 2023; 24(15): 12317. DOI: [10.3390/ijms241512317](https://doi.org/10.3390/ijms241512317)
63. Hu W, Zi Z, Jin Y, Li G, Shao K, Cai Q, et al. CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions. *Cancer Immunol Immunother*. 2019; 68: 365-377. DOI: [10.1007/s00262-018-2281-2](https://doi.org/10.1007/s00262-018-2281-2)
64. Vakulskas CA, and Behlke MA. Evaluation and reduction of CRISPR off-target cleavage events. *Nucleic Acid Ther*. 2019; 29(4): 167-174. DOI: [10.1089/nat.2019.0790](https://doi.org/10.1089/nat.2019.0790)
65. Newman A, Starrs L, and Burgio G. Cas9 cuts and consequences; Detecting, predicting, and mitigating CRISPR/Cas9 on-and off-target damage. *Bioessays*. 2020; 42(9): 2000047. DOI: [10.1002/bies.202000047](https://doi.org/10.1002/bies.202000047)
66. Tycko J, Wainberg M, Marinov GK, Ursu O, Hess GT, Ego BK, et al. Mitigation of off-target toxicity in CRISPR-Cas9 screens for essential non-coding elements. *Nat Commun*. 2019; 10(1): 4063. DOI: [10.1038/s41467-019-11955-7](https://doi.org/10.1038/s41467-019-11955-7)
67. Zhang S, Shen J, Li D, and Cheng Y. Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing. *Theranostics*. 2021; 11(2): 614-648. DOI: [10.7150/thno.47007](https://doi.org/10.7150/thno.47007)
68. Amirkhanov RN, and Stepanov GA. Systems of delivery of CRISPR/Cas9 ribonucleoprotein complexes for genome editing. *Russ J Bioorg Chem*. 2019; 45: 431-437. DOI: [10.1134/S1068162019060025](https://doi.org/10.1134/S1068162019060025)
69. DeWitt MA, Corn JE, and Carroll D. Genome editing via delivery of Cas9 ribonucleoprotein. *Methods*. 2017; 121: 9-15.

- DOI: [10.1016/j.ymeth.2017.04.003](https://doi.org/10.1016/j.ymeth.2017.04.003)
70. Crudele JM and Chamberlain JS. Cas9 immunity creates challenges for CRISPR gene editing therapies. *Nat Commun.* 2018; 9(1): 3497. DOI: [10.1038/s41467-018-05843-9](https://doi.org/10.1038/s41467-018-05843-9)
 71. Mehta A, and Merkel OM. Immunogenicity of Cas9 protein. *J Pharm Sci.* 2020; 109(1): 62-67. DOI: [10.1016/j.xphs.2019.10.003](https://doi.org/10.1016/j.xphs.2019.10.003)
 72. Seow Y, and Wood MJ. Biological gene delivery vehicles: Beyond viral vectors. *Mol Ther.* 2009; 17(5): 767-777. DOI: [10.1038/mt.2009.41](https://doi.org/10.1038/mt.2009.41)
 73. Yi W, Hu S, Qian X, Yan W, and Li Y. Synthetic biology-based engineering cells for drug delivery. *Exploration.* 2025; 5(2): 2381-2395. DOI: [10.1002/EXP.20240095](https://doi.org/10.1002/EXP.20240095)
 74. Youssef E, Fletcher B, and Palmer D. Enhancing precision in cancer treatment: the role of gene therapy and immune modulation in oncology. *Front Med.* 2025; 11: 1527600. DOI: [10.3389/fmed.2024.1527600](https://doi.org/10.3389/fmed.2024.1527600)
 75. de Almeida NA, Ribeiro CR, Raposo JV, and de Paula VS. Immunotherapy and gene therapy for oncoviruses infections: A review. *Viruses.* 2021; 13(5): 822. DOI: [10.3390/v13050822](https://doi.org/10.3390/v13050822)
 76. Lin D, Shen Y, and Liang T. Oncolytic virotherapy: Basic principles, recent advances and future directions. *Signal Transduct Target Ther.* 2023; 8(1): 156. DOI: [10.1038/s41392-023-01407-6](https://doi.org/10.1038/s41392-023-01407-6)
 77. Harrington K, Freeman DJ, Kelly B, Harper J, and Soria JC. Optimizing oncolytic virotherapy in cancer treatment. *Nat Rev Drug Discov.* 2019; 18(9): 689-706. DOI: [10.1038/s41573-019-0029-0](https://doi.org/10.1038/s41573-019-0029-0)
 78. Zhang D, Hussain A, Manghwar H, Xie K, Xie S, Zhao S, et al. Genome editing with the CRISPR-Cas system: An art, ethics and global regulatory perspective. *Plant Biotechnol J.* 2020; 18(8): 1651-1669. DOI: [10.1111/pbi.13383](https://doi.org/10.1111/pbi.13383)
 79. Asquer A, and Krachkovskaya I. Uncertainty, institutions and regulatory responses to emerging technologies: CRISPR Gene editing in the US and the EU (2012-2019). *Regul Gov.* 2021; 15(4): 1111-1127. DOI: [10.1111/rego.12335](https://doi.org/10.1111/rego.12335)
 80. Souto EB, Blanco-Llamero C, Krambeck K, Kiran NS, Yashaswini C, Postwala H, et al. Regulatory insights into nanomedicine and gene vaccine innovation: Safety assessment, challenges, and regulatory perspectives. *Acta Biomater.* 2024; 177: 1-18. DOI: [10.1016/j.actbio.2024.04.010](https://doi.org/10.1016/j.actbio.2024.04.010)
 81. Mulvihill JJ, Capps B, Joly Y, Lysaght T, Zwart HA, Chadwick R, et al. Ethical issues of CRISPR technology and gene editing through the lens of solidarity. *Br Med Bull.* 2017; 122(1): 17-29. DOI: [10.1093/bmb/ldx002](https://doi.org/10.1093/bmb/ldx002)
 82. Evans JH. Setting ethical limits on human gene editing after the fall of the somatic/germline barrier. *Proc Natl Acad Sci USA.* 2021; 118(22): e2004837117. DOI: [10.1073/pnas.2004837117](https://doi.org/10.1073/pnas.2004837117)
 83. Sadr S, Ahmadi Simab P, Niazi M, Yousefsani Z, Lotfalizadeh N, Hajjafari A, et al. Anti-inflammatory and immunomodulatory effects of mesenchymal stem cell therapy on parasitic drug resistance. *Expert Rev Anti Infect Ther.* 2024; 22(6): 435-451. DOI: [10.1080/14787210.2024.2360684](https://doi.org/10.1080/14787210.2024.2360684)
 84. Sanchez-Guijo F, Vives J, Ruggeri A, Chabannon C, Corbacioglu S, Dolstra H, et al. Current challenges in cell and gene therapy: A joint view from the European committee of the International society for cell and gene therapy (ISCT) and the European society for blood and marrow transplantation (EBMT). *Cytotherapy.* 2024; 26(7): 681-685. DOI: [10.1016/j.jcyt.2024.02.007](https://doi.org/10.1016/j.jcyt.2024.02.007)